PureTech Appoints UBS as UK Corporate Broker

Rhea-AI Summary

PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of UBS as its UK Corporate Broker. The company, which is dual-listed on Nasdaq and London Stock Exchange, made this strategic move to enhance its corporate brokerage services in the United Kingdom.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker.

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250105208105/en/

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

Source: PureTech Health plc

FAQ

What does UBS's appointment as corporate broker mean for PureTech (PRTC)?

UBS's appointment as PureTech's UK Corporate Broker means they will serve as an intermediary between the company and institutional investors in the UK market, providing corporate advisory and market-making services.

Why did PureTech (PRTC) choose UBS as its UK Corporate Broker?

The specific reasons for choosing UBS were not disclosed in the announcement. However, UBS is a major global financial institution with significant experience in corporate broking services.

What services will UBS provide to PureTech (PRTC) as corporate broker?

As a corporate broker, UBS will typically provide services including market making, institutional investor relations, corporate advisory, and assistance with capital market transactions for PureTech in the UK market.

How might UBS's appointment affect PureTech's (PRTC) UK market presence?

UBS's appointment could potentially enhance PureTech's visibility and relationships with institutional investors in the UK market, given UBS's extensive network and expertise in corporate broking services.